From development of the first active pharmaceutical ingredient to production of first finished dosage forms, AMEGA Biotech became a leading player for the production and commercialization of biotech-derived pharmaceuticals
[row_scroll entrance=”fly-right” exit=”fly-up”]
» 2005 / 2006
ACQUISITION OF GEMA AND ZELLTEK
AMEGA Biotech starts operations in 2005 with the acquisition of both companies. In this way, an innovative biotechnology project is born for the development, production and commercialization of biotech-derived pharmaceuticals.
[row_scroll entrance=”fly-right” exit=”fly-up”]
[row_scroll entrance=”fly-right” exit=”fly-up”]
» 2009
APPROVAL FROM THE MINISTRY OF HEALTH (ANMAT) AS LABORATORY OF MEDICINAL SPECIALTIES
GEMABIOTECH becomes the first producer of Active Pharmaceutical Ingredients of biotech origin authorized by ANMAT and one of the first biotech production sites approved in Latin America.
[row_scroll entrance=”fly-right” exit=”fly-up”]
[row_scroll entrance=”fly-right” exit=”fly-up”]
» 2010
PRODUCTION OF INTERFERON BETA-1A FINISHED DOSAGE FORM
AMEGA Biotech started the path to development and commercialization of Finished Dosage Forms. Interferon Beta-1a is the first finished product developed for the international market.
[row_scroll entrance=”fly-right” exit=”fly-up”]
[row_scroll entrance=”fly-right” exit=”fly-up”]
» 2013
APPROVAL OF THE FIRST FINISHED DOSAGE FORMS ABROAD
First marketing authorizations were granted to Hemastim (Erythropoietin) in Mauritania and Gabon and to Peg Neutropine (Peg Filgrastim) in Ecuador, thus increasing AMEGA Biotech operations overseas.
[row_scroll entrance=”fly-right” exit=”fly-up”]
[row_scroll entrance=”fly-right” exit=”fly-up”]
» 2014
LAUNCH OF FINISHED DOSAGE FORMS IN ARGENTINA
Hemastim (Erythropoietin), Neutropine (Filgrastim) and Peg Neutropine (Peg-Filgrastim) were the first products launched in the local market, entirely developed and commercialized by GEMA Biotech.
[row_scroll entrance=”content-fly-right” exit=”fly-up”]
2005
2009
2009
2009
2010
2011
2013
2014
2015
[row_scroll entrance=”fly-left” exit=”fly-up”]
[row_scroll entrance=”fly-left” exit=”fly-up”]
» 2009
INAUGURATION OF SANTA FE PRODUCTION SITE (ZELLTEK)
Production of biotech-derived Active Pharmaceutical Ingredients for human health was consolidated through inauguration of Zelltek manufacturing site in Parque Tecnológico Litoral Centro (Santa Fe, Argentina).
[row_scroll entrance=”fly-left” exit=”fly-up”]
[row_scroll entrance=”fly-left” exit=”fly-up”]
» 2009
GRANTING OF FSBIO AND FSNANO FUNDS
AMEGA Biotech strengthened its national positioning obtaining both subsidies awarded by the Ministry of Science, Technology and Productive Innovation. Through public-private consortiums, GEMA Biotech and Zelltek partner up with Universidad Nacional del Litoral and industry-related companies to contribute to the scientific-technological development of the country.
[row_scroll entrance=”fly-left” exit=”fly-up”]
[row_scroll entrance=”fly-left” exit=”fly-up”]
» 2011
FIRST FINISHED PRODUCT REGISTRATION CERTIFICATES OBTAINED IN ARGENTINA
First Finished Product registration certificates are obtained from the Local Ministry of Health (ANMAT).
[row_scroll entrance=”fly-left” exit=”fly-up”]
[row_scroll entrance=”fly-left” exit=”fly-up”]
» 2013
START OF CLINICAL TRIALS IN ARGENTINA
AMEGA Biotech consolidated its product registration platform for biopharmaceutical products with its own brand. This milestone also paved the way for product approvals in leading markets.
[row_scroll entrance=”fly-left” exit=”fly-up”]
[row_scroll entrance=”content-fly-left” exit=”fly-up”]
AMEGA BIOTECH, 10 YEARS
From development of the first active pharmaceutical ingredient to production of first finished dosage forms, AMEGA Biotech became a leading player for the production and commercialization of biotech-derived pharmaceuticals.
» 2005 / 2006
ACQUISITION OF GEMA AND ZELLTEK
AMEGA Biotech starts operations in 2005 with the acquisition of both companies. In this way, an innovative biotechnology project is born for the development, production and commercialization of biotech-derived pharmaceuticals.
» 2009
INAUGURATION OF SANTA FE PRODUCTION SITE (ZELLTEK)
Production of biotech-derived Active Pharmaceutical Ingredients for human health was consolidated through inauguration of Zelltek manufacturing site in Parque Tecnológico Litoral Centro (Santa Fe, Argentina).
» 2009
APPROVAL FROM THE MINISTRY OF HEALTH (ANMAT) AS LABORATORY OF MEDICINAL SPECIALTIES
GEMABIOTECH becomes the first producer of Active Pharmaceutical Ingredients of biotech origin authorized by ANMAT and one of the first biotech production sites approved in Latin America.
» 2009
GRANTING OF FSBIO AND FSNANO FUNDS
AMEGA Biotech strengthened its national positioning obtaining both subsidies awarded by the Ministry of Science, Technology and Productive Innovation. Through public-private consortiums, GEMA Biotech and Zelltek partner up with Universidad Nacional del Litoral and industry-related companies to contribute to the scientific-technological development of the country.
» 2010
PRODUCTION OF INTERFERON BETA-1A FINISHED DOSAGE FORM
AMEGA Biotech started the path to development and commercialization of Finished Dosage Forms. Interferon Beta-1a is the first finished product developed for the international market.
» 2011
FIRST FINISHED PRODUCT REGISTRATION CERTIFICATES OBTAINED IN ARGENTINA
First Finished Product registration certificates are obtained from the Local Ministry of Health (ANMAT).
» 2013
APPROVAL OF THE FIRST FINISHED DOSAGE FORMS ABROAD
First marketing authorizations were granted to Hemastim (Erythropoietin) in Mauritania and Gabon and to Peg Neutropine (Peg Filgrastim) in Ecuador, thus increasing AMEGA Biotech operations overseas.
» 2013
START OF CLINICAL TRIALS IN ARGENTINA
AMEGA Biotech consolidated its product registration platform for biopharmaceutical products with its own brand. This milestone also paved the way for product approvals in leading markets.
» 2014
LAUNCH OF FINISHED DOSAGE FORMS IN ARGENTINA
Hemastim (Erythropoietin), Neutropine (Filgrastim) and Peg Neutropine (Peg-Filgrastim) were the first products launched in the local market, entirely developed and commercialized by GEMA Biotech.
AMEGA BIOTECH, 10 YEARS
From development of the first active pharmaceutical ingredient to production of first finished dosage forms, AMEGA Biotech became a leading player for the production and commercialization of biotech-derived pharmaceuticals.